OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Disis on the Rationale For Investigating PRGN-3005 With/Without Lymphodepletion in Ovarian Cancer

September 26th 2023

Mary “Nora” Disis, MD, discusses the rationale for investigating the efficacy and optimal delivery of PRGN-3005 autologous UltraCAR T cells in patients with advanced stage platinum-resistant ovarian cancer.

Dr Hecht on the Investigation of the Novel CAR T-Cell Therapy A2B530 in Solid Tumors

September 25th 2023

J. Randolph (Randy) Hecht, MD, discusses the observational BASECAMP-1 study and the investigation of HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in the phase 1/2 EVEREST-1 study, which will investigate A2B530 in patients with solid tumors.

Dr Qin on Emerging Treatment Options in ccRCC

September 25th 2023

Qian (Janie) Qin, MD, discusses emerging treatment regimens for patients with advanced clear cell renal cell carcinoma.

Dr Chari on the Safety Profile of Talquetamab in Relapsed/Refractory Multiple Myeloma

September 25th 2023

Ajai Chari, MD, director, discusses the safety profile of talquetamab following the drug’s FDA approval for patients with relapsed/refractory multiple myeloma.

Dr Riess on the Initial Efficacy of the IO102-IO103 Vaccine Plus Pembrolizumab in Lung Adenocarcinoma

September 25th 2023

Jonathan W. Riess, MD, MS, discusses preliminary results from a phase 2 trial of the IO102-IO103 immuno-modulating cancer vaccine plus pembrolizumab in patients with metastatic non–small cell lung cancer adenocarcinoma.

Dr Aerts on Results From the DENIM Trial of Dendritic Cell Vaccination in Mesothelioma

September 25th 2023

Joachim G. J. V. Aerts, MD, PhD, discusses findings from the phase 3 DENIM trial in patients with mesothelioma, which was presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.

Experts Highlight Their Biggest Takeaways from the 2023 SOHO Annual Meeting

September 25th 2023

Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.

Dr Daver on the Investigation of Uproleselan Plus Azacitidine and Venetoclax in AML

September 22nd 2023

Naval G. Daver, MD, discusses the rationale for an ongoing phase 1 trial investigating uproleselan in combination with azacitidine and venetoclax in patients with treatment-naïve acute myeloid leukemia.

Dr Jänne on Trastuzumab Deruxtecan in HER2-Mutant NSCLC

September 22nd 2023

Pasi A. Jänne, MD, PhD, discusses key findings from the primary analysis of the phase 2 DESTINY-Lung02 trial in patients with HER2-mutant non–small cell lung cancer.

Dr Pothuri on the Use of ADCs in Ovarian Cancer

September 22nd 2023

Bhavana Pothuri, MD, discusses the use of antibody-drug conjugates in patients with ovarian cancer and AEs to be aware of when treating patients with these therapies.

Dr Usmani on Unmet Needs in the Treatment of High-Risk Multiple Myeloma

September 22nd 2023

Saad Z. Usmani, MD, MBA, FACP, discusses unmet needs in patients with high-risk multiple myeloma being treated in the frontline setting, highlighting areas of potential further exploration within this landscape.

Dr Hecht on Barriers to CAR T-Cell Therapy Treatment in Solid Tumors

September 22nd 2023

J. Randolph (Randy) Hecht, MD, discusses barriers to treatment with CAR T-cell therapy in patients with solid tumors, highlighting various efforts that investigators are spearheading to address these unmet needs.

Dr Di Federico on an Analysis of TTF-1 Expression in Lung Adenocarcinoma

September 22nd 2023

Alessandro Di Federico, MD, discusses findings from a study investigating the correlation between TTF-1 expression and outcomes with immunotherapy-based treatments in patients with lung adenocarcinoma.

Dr Qin on Ongoing Investigations of Belzutifan Combinations in Advanced ccRCC

September 22nd 2023

Qian (Janie) Qin, MD, discusses several belzutifan combination strategies under investigation in advanced clear cell renal cell carcinoma.

Dr Boughey on Defining Optimal Candidates For Surgical De-Escalation in Breast Cancer

September 22nd 2023

Judy C. Boughey, MD, discusses key characteristics that define the ideal population for surgical de-escalation among patients with breast cancer.

Dr Zhang on the Use of Radiation Therapy for Oligometastatic RCC

September 22nd 2023

Tian Zhang, MD, MHS, discusses the use of radiation therapy for patients with oligometastatic renal cell carcinoma.

Dr Esteva on the Use of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

September 22nd 2023

Francisco J. Esteva, MD, PhD, discusses the use of CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.

Dr Liu on the Frequency of Activating ERBB2 and ERBB3 Alterations in NSCLC

September 22nd 2023

Dazhi Liu, PharmD, MS, BCOP, discusses findings from a real-world analysis of the frequency of ERBB2 and ERBB3 alterations in patients with non–small cell lung cancer and the efficacy of liquid vs tissue biopsies for detecting these alterations.

Dr Cannon on the Use of Dendritic Cell Vaccines in Ovarian Cancer

September 21st 2023

Martin Cannon, PhD, discusses the use of dendritic cell vaccines and immune checkpoint inhibitors in ovarian cancer.

Dr. Schetelig on the Use of Induction Chemotherapy Prior to Allo-HCT in Relapsed/Refractory AML

September 21st 2023

Johannes Schetelig, MD, MSc, discusses whether patients with active relapsed/refractory acute myeloid leukemia (AML) should receive remission induction chemotherapy prior to undergoing allogenic hematopoietic stem cell transplant (allo-HCT).